Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Terminated 6Unknown 5Recruiting 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Recurrence 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Drug Evaluation × Clear all
NCT05758610 2024-05-08

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Myeloid, Acute

NCT05913141 2023-06-22

PDO/PDO-TIL/PDOTS for Drug Screen

Shanghai Zhongshan Hospital

Recruiting
30 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡